Adverse Event Reporting and Management

Query Generation from AE Forms in Clinical Trials

Posted on digi By digi

In clinical trials, queries are the formal mechanism by which data managers communicate discrepancies, missing values, or inconsistencies back to investigators. Within adverse event (AE) forms in electronic case report forms (eCRFs), queries are essential to ensure accurate, complete, and regulatory-compliant safety data. Regulatory authorities such as the FDA, EMA, and MHRA expect sponsors to demonstrate a robust query management process that identifies and resolves errors in AE documentation prior to database lock and regulatory submission.
Click to read the full article.

Adverse Event Reporting and Management, AE Data Collection in eCRFs

Cross-Check of AE Data with Concomitant Medications in Clinical Trials

Posted on digi By digi

Adverse event (AE) documentation cannot be reviewed in isolation. Regulators including the FDA, EMA, and MHRA expect sponsors to cross-check AE entries in electronic case report forms (eCRFs) with concomitant medication data. This reconciliation ensures that causality assessments are accurate, potential drug–drug interactions are identified, and discrepancies are resolved prior to database lock and regulatory submission.
Click to read the full article.

Adverse Event Reporting and Management, AE Data Collection in eCRFs

Ensuring Completeness in AE Forms in Clinical Trials

Posted on digi By digi

In clinical trials, adverse event (AE) documentation serves as the foundation of patient safety monitoring and regulatory reporting. Regulators such as the FDA, EMA, MHRA, and CDSCO expect AE forms within electronic case report forms (eCRFs) to be complete, consistent, and inspection-ready. Incomplete AE forms are one of the most common inspection findings, often cited as major deficiencies that delay regulatory submissions or compromise data reliability.
Click to read the full article.

Adverse Event Reporting and Management, AE Data Collection in eCRFs

Causality Assessment Tools in Adverse Event Evaluation (WHO-UMC Scale and Others)

Posted on digi By digi

When an adverse event (AE) occurs in a clinical trial, one of the most important steps is assessing whether the event is related to the investigational product or to other factors such as underlying disease, concomitant medication, or procedures. Regulatory agencies such as the FDA, EMA, MHRA, and CDSCO require that sponsors and investigators use causality assessment tools or structured methods to evaluate the relationship between AEs and study drugs. This assessment influences not only regulatory reporting (e.g., expedited reports of SAEs and SUSARs) but also overall drug safety profiles and labeling decisions.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Investigator vs Sponsor Roles in Causality Assessment

Posted on digi By digi

Causality assessment is central to determining whether an adverse event (AE) is related to an investigational product (IP) in a clinical trial. Both investigators and sponsors play crucial roles in this process, but their responsibilities are distinct. Regulators such as the FDA, EMA, MHRA, and ICH guidance clearly outline the expectations for each stakeholder. Misalignment or poor documentation between investigator and sponsor causality assessments is one of the most common findings in regulatory inspections.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Severity Grading of Adverse Events Using CTCAE Guidelines

Posted on digi By digi

Severity grading is one of the most critical aspects of adverse event (AE) assessment in clinical trials. Regulators including the FDA, EMA, and MHRA require investigators to classify the intensity of each AE using standardized methods to ensure consistent interpretation across sites and studies. The Common Terminology Criteria for Adverse Events (CTCAE), developed by the U.S. National Cancer Institute (NCI), is the most widely used grading system, particularly in oncology but increasingly applied in other therapeutic areas.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Determining the Relationship of Adverse Events to Investigational Products

Posted on digi By digi

In clinical trials, one of the most important judgments investigators and sponsors make is whether an adverse event (AE) is related to the investigational product (IP). Regulatory authorities such as the FDA, EMA, MHRA, and ICH guidelines require clear attribution of AEs to the IP, as this impacts expedited reporting, aggregate analyses, drug labeling, and ultimately the benefit–risk assessment of the product. Misclassification of causality can delay safety reporting, distort clinical trial outcomes, and trigger regulatory findings.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Training Investigators on Causality Judgments in Clinical Trials

Posted on digi By digi

In clinical trials, the causality judgment—deciding whether an adverse event (AE) is related to an investigational product (IP)—is one of the most critical responsibilities of investigators. Regulators including the FDA, EMA, MHRA, and ICH guidelines mandate accurate and well-documented causality assessments. However, causality determinations are inherently subjective and vary significantly among investigators, often leading to discrepancies with sponsor evaluations. To minimize subjectivity, ensure consistency, and avoid inspection findings, structured training programs for investigators are indispensable.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Causality Re-Assessment After Unblinding in Clinical Trials

Posted on digi By digi

In blinded clinical trials, investigators and sponsors assess adverse event (AE) causality without knowing whether a participant received the investigational product (IP), placebo, or comparator. While this preserves study integrity, it also limits the ability to make fully informed causality judgments. Once unblinding occurs—at interim analysis, database lock, or trial completion—it becomes necessary to reassess causality with full knowledge of treatment allocation.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments

Causality Re-Assessment After Unblinding in Clinical Trials

Posted on digi By digi

Blinded clinical trials are designed to minimize bias by concealing treatment allocation from both investigators and participants. While this methodology strengthens the validity of efficacy outcomes, it presents unique challenges in adverse event (AE) causality assessment. During the blinded phase, investigators must assign causality without knowing whether the participant received the investigational product (IP), a comparator, or a placebo. As a result, causality judgments are often tentative, based only on clinical presentation, timing, and plausibility. Once unblinding occurs—whether at interim analysis, final database lock, or emergency medical need—regulatory authorities expect sponsors to reassess causality with the knowledge of treatment assignment.
Click to read the full article.

Adverse Event Reporting and Management, Causality and Severity Assessments